证券代码：300003 证券简称：乐普医疗 公告编号：2023-051 乐普（北京）医疗器械股份有限公司 第六届董事会第三次会议决议公告 具体内容详见公司同日披露于巨潮资讯网的《关于使用部分闲置募集资金 暂时补充流动资金的公告》（公告编号：2023-057）。 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 乐普（北京）医疗器械股份有限公司（以下简称：公司）第六届董事会第三 次会议于 2023 年 8 月 25 日在北京市昌平区超前路 37 号公司会议室以现场及 通讯相结合的方式召开，会议通知于 2023 年 8 月 20 日以邮件方式发出。会议 应出席董事 7 名，实际出席董事 7 名。本次会议召开符合《公司法》及《公司章 程》的相关规定。会议由董事长蒲忠杰先生主持，公司监事会全体成员列席了本 次会议，出席会议的董事逐项审议并以记名方式投票表决通过了如下决议： 一、审议《关于公司 2023 年半年度报告及报告摘要》的议案 二、审议《2023 年半年度募集资金存放与使用情况专项报告》的议案 具体内容详见公司同日披露于巨潮资讯网的《2023 年半年度募集资金存放 与使 ...

乐普（北京）医疗器械股份有限公司 公司章程 乐普（北京）医疗器械股份有限公司 章 程 （2023 年 8 月修订稿） | 第一章 | 总 则 3 | | --- | --- | | 第二章 | 经营宗旨和范围 4 | | 第三章 | 股 份 5 | | 第一节 | 股东持股情况 5 | | 第二节 | 股份增减和回购 6 | | 第三节 | 股份转让 8 | | 第四章 | 股东和股东大会 8 | | 第一节 | 股东 8 | | 第二节 | 股东大会的一般规定 11 | | 第三节 | 股东大会的召集 14 | | 第四节 | 股东大会的提案与通知 15 | | 第五节 | 股东大会的召开 17 | | 第六节 | 股东大会的表决和决议 21 | | 第五章 | 董事会 26 | | 第一节 | 董事 26 | | 第二节 | 独立董事 30 | | 第三节 | 董事会 31 | | 第六章 | 高级管理人员 37 | | 第七章 | 监事会 39 | | 第一节 | 监事 39 | | 第二节 | 监事会 41 | | 第三节 | 监事会决议 42 | | 第八章 | 财务会计制度、利润分配和审计 43 ...

乐普（北京）医疗器械股份有限公司 上市公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 2）合计金额有尾差是四舍五入所致。 注：①表中非经营性占用部分，关联方范围依照《创业板上市规则》确定。②无控股股东、实际控制人的公司，存在第一大股东或第一大股东关联人非经 营性占用资金的，也应填写本表非经营性占用部分。 | 乐普创一生物科技（上海）有 | 上市公司参股公司子 | 应收账款 | | 0.47 | | | 0.47 | 销售商品 | 经营性往来 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 限公司 | 公司 | | | | | | | | | | 北京普润医疗器械有限公司 | 上市公司参股公司 | 应收账款 | 673.05 | 35.79 | | 708.84 | | 销售商品 | 经营性往来 | | 北京海金格医药科技股份有 | 上市公司参股公司 | 预付账款 | 288.10 | 2,056.78 | | 1,310.36 | 1,034.53 | 接受劳务 | 经营性往来 | | 限公司 | | | ...

证券代码：300003 证券简称：乐普医疗 乐普（北京）医疗器械股份有限公司 投资者关系活动记录表 编号：2023-01 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 ■业绩说明会 | | | □新闻发布会 □路演活动 | | 类别 | □现场参观 | | | □其他 | | 参与单位名称及 | | | | 261 家境内外机构共 379 名参会人员，详见附件明细 | | 人员姓名 | | | 时间 | 年 月 日 2023 4 26 | | 地点 | 电话会议 | | 上市公司接待人 | 董事长 蒲忠杰 | | | 财务总监 王泳 | | 员姓名 | 董事会秘书 江维娜 | | | 蒲总：感谢新老朋友们参会，大家晚上好！今天我主要从 | | | 以下五方面给大家汇报：第一，经营数据回顾；第二，创新与 | | | 发展公司做出的努力；第三，公司新增长极消费医疗正在崛起； | | | 四，慢病领域人工智能应用；第五，国际化战略与途径。 | | | （1） 经营数据：在政策扰动和疫情管控大环境下， | | 投资者关系活动 | 2021、2022 年这两年 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 2,437,202,386.92, a decrease of 4.39% compared to CNY 2,549,111,243.52 in the same period last year[4] - Net profit attributable to shareholders increased by 9.45% to CNY 596,924,222.49, up from CNY 545,393,656.31 year-on-year[4] - The net profit for the first quarter of 2023 was CNY 618.32 million, an increase of 10% compared to CNY 562.13 million in the same period last year[21] - The total comprehensive income attributable to the parent company was CNY 638.69 million, up from CNY 419.81 million year-on-year[22] - Basic earnings per share increased to CNY 0.3205 from CNY 0.3054 in the previous year, reflecting a growth of approximately 6.8%[22] - Operating profit for the quarter was CNY 699.84 million, slightly up from CNY 684.52 million in the same quarter of the previous year[21] Cash Flow and Liquidity - The net cash flow from operating activities showed a significant decline, with a net outflow of CNY 134,203,435.01, a decrease of 129.89% compared to a net inflow of CNY 448,932,891.19 in the previous year[4] - Cash and cash equivalents at the end of the period were CNY 5,297,999,204.12, a decrease of 3.1% from CNY 5,467,278,785.39 at the beginning of the year[18] - Cash and cash equivalents at the end of the period were CNY 5.17 billion, down from CNY 3.53 billion at the end of the previous year[24] - Investment activities resulted in a net cash outflow of CNY 212.41 million, an improvement from a net outflow of CNY 436.73 million in the same period last year[24] - The company experienced a foreign exchange loss of CNY 42.62 million, impacting the overall cash position[24] Assets and Liabilities - The company’s total assets at the end of the reporting period were CNY 24,559,902,516.86, reflecting a slight increase of 0.31% from the previous year[4] - Total liabilities decreased to CNY 7,477,548,984.26, down from CNY 8,113,549,880.82 at the beginning of the year[19] - The company's equity attributable to shareholders increased to CNY 15,823,636,468.24, compared to CNY 15,146,202,761.30 at the beginning of the year[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 83,934, with the top ten shareholders holding a combined 60.94% of shares[12] - The largest shareholder, China Shipbuilding Industry Group Company, holds 12.98% of shares, totaling 244,063,788 shares[12] - WP Medical Technologies, Inc. is the second-largest shareholder with 12.13%, holding 228,074,749 shares[12] - The top ten shareholders include various investment funds and individuals, with the largest being state-owned entities and private investors[12] - The company has a significant portion of shares pledged, with 171,056,062 shares pledged by shareholder Pu Zhongjie[14] Operational Highlights - The cardiovascular intervention product line achieved positive growth despite a general decline in sales, with the medical services and health management segment growing by 16.06% year-on-year[8] - Research and development expenses increased to CNY 229,686,257.30, up 8.1% from CNY 212,393,810.51 in the previous year[20] - Total operating costs decreased to CNY 1,749,019,988.44, down 5% from CNY 1,840,886,155.20 year-over-year[20] - Gross profit margin improved to approximately 28.3%, compared to 26.5% in the previous year[20] Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[20]

Financial Performance - The company reported significant financial metrics in the annual report, including total revenue and net profit figures, which are crucial for assessing performance [7]. - The company's operating revenue for 2022 was ¥10,609,442,080.61, a decrease of 0.47% compared to 2021 [12]. - Net profit attributable to shareholders for 2022 was ¥2,202,809,390.54, an increase of 28.12% year-over-year [12]. - The net profit after deducting non-recurring gains and losses was ¥2,142,486,458.55, reflecting a 15.50% increase from the previous year [12]. - The total assets at the end of 2022 amounted to ¥24,484,033,145.01, representing an 18.29% increase from the end of 2021 [12]. - The company's basic earnings per share for 2022 was ¥1.2223, up 27.38% from ¥0.9596 in 2021 [12]. - The cash flow from operating activities for 2022 was ¥2,790,709,307.02, a decrease of 8.86% compared to 2021 [12]. - The weighted average return on equity for 2022 was 17.60%, an increase of 1.60% from 16.00% in 2021 [12]. Market Strategy and Expansion - The company is focused on expanding its market presence and developing new products and technologies to enhance its competitive edge [4]. - The company has a strategic plan for mergers and acquisitions to bolster its growth and market share in the medical device sector [4]. - The company plans to continue leveraging its competitive advantages in R&D, cost control, and supply management to enhance market share amid ongoing procurement reforms [25]. - The company aims to expand its market share in cardiovascular intervention by leveraging its competitive advantages and responding proactively to volume-based procurement policies [30]. - The company has established a presence in over 150 countries and regions, with a focus on increasing overseas sales and brand recognition through participation in global medical device exhibitions [32]. - The company raised USD 220 million through GDR listing on the Swiss Six Swiss Exchange, which will support its international expansion efforts [32]. - The company is exploring vertical segments in ophthalmology, dentistry, and dermatology through a combination of self-incubation and acquisitions, marking 2023 as the year for consumer healthcare growth [31]. Research and Development - The company is actively investing in research and development to innovate and improve its product offerings [4]. - The company has filed a total of 1,650 patents and has over 600 products listed domestically and internationally as of December 31, 2022 [26]. - The company has received 569 NMPA approvals for Class II and III medical devices, 33 FDA certifications, and 224 CE certifications [26]. - The company plans to launch several key innovative products from 2023 to 2026, including a blood flow reserve measurement device and a drug-coated balloon, enhancing its product pipeline in cardiovascular intervention [31]. - The company is focusing on innovative solutions to meet clinical needs, such as the self-expanding ScienCrown® valve, which offers significant advantages over existing products [40]. - The company is developing a new generation of non-invasive blood glucose monitoring devices, with clinical trials nearing completion and meeting registration standards for sensitivity and accuracy [73]. - The company is actively exploring AI applications in personalized treatment recommendations for chronic disease patients, particularly in diabetes and hypertension [73]. Governance and Compliance - The company’s governance structure and compliance with regulatory requirements were outlined, ensuring accountability and integrity in operations [4]. - The company is committed to maintaining transparency and accuracy in its financial reporting, as stated by its management team [2]. - The company has established a performance evaluation and incentive system linking executive compensation to business performance, promoting transparency [161]. - The company strictly adheres to governance regulations, ensuring independent operation and management separate from its controlling shareholders [157]. - The company maintains independence from its controlling shareholders in terms of business operations, personnel, and financial management [166]. Risk Management - The management discussion highlighted potential risks that the company may face in the future, which is essential for investors to consider [2]. - The company faces risks from bulk procurement policies affecting medical consumables and generic drugs, which may lead to price reductions [147]. - The company is committed to diversifying its product portfolio to mitigate the impact of bulk procurement on revenue and profit [147]. - The company is enhancing its R&D capabilities to address risks associated with product development and regulatory approvals [148]. Investor Relations - The company held multiple investor communication events, with 243 participants in the half-year meeting and 378 in the third-quarter meeting, indicating strong investor interest [154]. - The company actively manages investor relations through various channels, enhancing communication and interaction with investors [163]. Employee Development - The company has established a comprehensive training system for employee development [195]. - The total number of employees at the end of the reporting period is 10,652, with 2,115 in the parent company and 8,537 in major subsidiaries [193]. - The professional composition includes 3,622 production personnel, 3,409 sales personnel, 2,663 technical personnel, 278 financial personnel, and 680 administrative personnel [193]. Profit Distribution - The company proposed a profit distribution plan, distributing a cash dividend of 3.41 CNY (including tax) for every 10 shares, with no bonus shares issued [3]. - The total cash dividend distributed was 880,967,306.55 yuan, which represents 100% of the distributable profit [199]. - The company has a cash dividend policy that requires a minimum of 20% of profits to be distributed as cash dividends during growth phases [199]. - The profit distribution plan complies with the company's articles of association and relevant regulations [197].

关于举行 2022 年度和 2023 年一季度网上业绩说明会公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 证券代码：300003 证券简称：乐普医疗 公告编号：2023-029 乐普（北京）医疗器械股份有限公司 特此公告。 乐普（北京）医疗器械股份有限公司 董事会 二○二三年四月二十五日 乐普（北京）医疗器械股份有限公司（以下简称：公司）《2022 年年度报 告》和《2023 年一季度报告》于 2023 年 4 月 26 日刊登于中国证监会创业板指 定的信息披露网站。为便于投资者进一步了解公司的生产经营情况，公司将于 2023 年 5 月 12 日（星期五）下午 15:00-17:00，以网络远程互动方式召开 2022 年度和 2023 年一季度网上业绩说明会。投资者可登陆全景网"投资者关系互动 平台"（https://ir.p5w.net）参与本次业绩说明会。 出席本次业绩说明会的人员有：公司董事长蒲忠杰先生，独立董事曲新女士， 董事会秘书江维娜女士，高级副总经理兼财务总监王泳女士，保荐代表人刘君女 士。 欢迎广大投资者积极参与！ ...

Group 1: Company Performance - In the first half of 2015, Lepu Medical achieved a profit growth of 36.6% across its business segments, including medical devices, pharmaceuticals, medical services, and mobile healthcare [4] - The medical device segment generated revenue of 112.96 million CNY, marking a year-on-year increase of 124.73% [5] - The pharmaceutical segment reported revenue of 436.78 million CNY, with a staggering year-on-year growth of 506.19%, and a net profit of 82.39 million CNY, up 212.57% [5] Group 2: Product Development and Innovation - The company is making significant progress in the development of fully absorbable stents, with 400 clinical data points collected and expected completion by the end of the year [6] - The dual-chamber pacemaker is anticipated to receive registration by the end of 2015, indicating a high probability of success [6] Group 3: Strategic Acquisitions and Market Expansion - Lepu Medical completed a mixed-ownership reform in June 2014, focusing on expanding into mobile healthcare related to cardiovascular diseases [6] - The company is targeting the rapidly growing field of surgical staplers, with an expected growth rate of 25% to 30% over the next 3 to 5 years [6] Group 4: Financial Management and Future Outlook - The company has a significant accounts receivable of over 1 billion CNY, primarily due to long payment terms with hospitals [13] - The expected growth rate for Clopidogrel is projected at 100% for the current year, with a forecast of 70% to 80% for the following year [12] Group 5: Market Trends and Customer Engagement - Lepu Medical has established over 300 grassroots clinics, enhancing its pharmaceutical sales and providing a comprehensive service model for patients [8] - The company is developing an O2O platform that connects grassroots clinics with online pharmacies, facilitating patient access to medications and services [8]

Business Strategy - The company aims to create a comprehensive cardiovascular health ecosystem, focusing on both traditional hospital channels and establishing its own traffic center for patient management [6][7] - The strategy includes building a health management community for patients post-PCI surgery, targeting a conversion rate of 30%-40% from the annual 500,000 PCI surgeries in China, potentially generating 1-2 billion RMB in drug sales [7][8] - The company emphasizes the importance of integrating its four business segments: medical devices, pharmaceuticals, mobile healthcare, and medical services, as each is essential for overall success [9][10] Market Position and Growth - The PCI surgery market is expected to grow by 15%-20% annually, with the company anticipating a stabilization in pricing after recent declines [10][11] - Currently, 70% of the company's profits come from stents, but this is projected to decrease to below 50% as the company diversifies its revenue streams [10] - The company is focusing on acquiring large-volume and specialized pharmaceuticals to enhance its market position [9][10] Product Development - The company is committed to maintaining leadership in cardiovascular medical devices, with a focus on innovative products like dual-chamber pacemakers and biodegradable stents [9][10] - The introduction of atorvastatin is seen as crucial for establishing a cardiovascular drug platform, addressing the significant market demand for lipid-lowering medications [18][19] Challenges and Future Outlook - The company identifies talent acquisition and management as its primary internal challenges, particularly in the mobile healthcare sector [13][14] - Regulatory policies regarding online prescription sales and multi-practice operations are viewed as potential bottlenecks, but the company believes in the inevitability of internet-based healthcare solutions [16][17] - The company plans to invest 50-100 million RMB annually in mobile healthcare initiatives, leveraging existing resources to minimize costs [15][16]